Ponatinib

The following compounds were used: oryzalin (36182; Sigma-Aldrich), 5-iodotubercidin (5-ITu) (I100; Sigma-Aldrich), PD-180970 (PZ0142; Sigma-Aldrich), PD-166326 (9000988; Cayman Chemical), PD-173955-Analog1 (SYN-1062; SYNkinase), ponatinib (CS-0204; CHEMSCENE), bosutinib (PZ0192; Sigma-Aldrich), bafetinib (A10119; AdooQ Bioscience), PP2 (P0042; Sigma-Aldrich), PP1 (BML-EI275; Enzo Life Sciences), 4-aminopyrazolo[3,4-d]pyrimidine (PP2-Analog1) (A1041; Tokyo Chemical Industry), 1-tert-butyl-1H-pyrazolo[3,4-d]pyrimidine-4-amine (PP2-Analog2) (GF-0723; Key Organics), PP3 (A2737; Tokyo Chemical Industry), and Src inhibitor1 (sc-204303; Santa Cruz Biotechnology) (Karni et al, 2002 (link); Wisniewski et al, 2002 (link); Hum et al, 2014 (link); Rossari et al, 2018 (link)).
Each compound was dissolved in DMSO and used at a final concentration of 10 μM in 0.1% DMSO, except for the dosage assay, and in oryzalin, which was used at 1 μM. oryzalin (10 μM) was used in the P. patens assay.

Dasatinib (98.44%), nilotinib (99.77%), and ponatinib (98.96%) were obtained from ChemScene; bosutinib (≥98%) was obtained from Cayman Chemical; HPLC‐grade acetonitrile was obtained from Merck KGaA; and potassium dihydrogen phosphate, phosphoric acid, HPLC‐grade methanol, and isopropanol were obtained from Nacalai Tesque. Pooled human serum was obtained from Cosmo Bio.